Patent intelligence · US
US 9518260
Pain treatment
Pain treatment
Patent details — US 9518260
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 13, 2016
- Expiration
- Dec 8, 2036
- Applicant
- Benitec Biopharma Limited
- Claims
- 25
- CPC classes
- A61P, A61P25/04
Quick answer
US 9518260 (Pain treatment) is held by Benitec Biopharma Limited. Status: granted. Granted Dec 13, 2016. Expires Dec 8, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Benitec Biopharma Limited
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61P, A61P25/04
More from Benitec Biopharma Limited
Related pharmaceutical patents in our USPTO index.
-
US 11932852
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11535851
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 11234994
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11142765
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 10898505
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 10000753
Age-related macular degeneration treatment
granted -
US 9410154
HBV treatment
granted
Frequently asked questions
What is US patent 9518260?
US 9518260 (Pain treatment) is held by Benitec Biopharma Limited. Status: granted. Granted Dec 13, 2016. Expires Dec 8, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9518260?
Benitec Biopharma Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 9518260 expire?
Our index shows an expiration date of Dec 8, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.